Title of Invention

A SYNERGISTIC HERBAL COMPOSITION

Abstract The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer, a method for preparing said synergistic herbal composition. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model.
Full Text FIELD OF THE INVENTION
The present invention relates to a synergistic herbal composition. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. The present invention also relates to a method for the preparation of the composition. The present invention further relates to a process for the treatment of gastric ulcer using the composition.
BACKGROUND OF THE INVENTION
Various theories have been proposed with respect to a cause of ulcer in human. In particular,
it has been elucidated that stress, taking of non-steroidal anti-inflammatory drugs for curing
rheumatic diseases, and the like are closely related to ulcer formation, mainly due to relatively
excess gastric or duodenal acid secretion. Accordingly it is important to suppress the acid
secretion in order to prevent ulcer formation and to cure it.
On the other hand it has been considered that Helicobacter pylori, which is a rod normally
existing in stomach, generates ammonia due to its strong urease activity, thereby inducing
ulcer. Since it persistently lives within mucus and mucosa, it becomes the greatest cause for
recurrence of ulcer. Accordingly, it has been considered that the recurrence of ulcer can be
prevented if this bacterium is sterilized.
A reference may be made to K. M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p1287,
published by Popular Prakashan Pvt. Ltd., Mumbai and K. R. Kirtikar in Indian Medicinal
Plants (1975) Vol. 1, p 608 published by Bishen Singh Mahendrapal Singh, Dehradun for the
medicinal properties of Blechnum orintale.
A reference may be made to P. K. Warrier in Indian Medicinal Plants—A compendium of 500
species (1994-1996) Vol. 5, p 396, and The Wealth of India (1950-1980), Vol.10 p. 556
published by Council of Scientific and Industrial Research for the various medicinal
properties of Vitis vinifera.
A reference may be made to K. Narayana Iyer and M. Kolammal in Pharmacognosy of
Ayurvedic Drugs (1963) Vol.2, p. 80, published by Department of Pharmacognosy,
University of Kerala, Trivandrum and The Wealth of India (1950-1980) Vol. 1, p. 34,
published by Council of Scientific and Industrial Research for the various medicinal
properties of Aegle marmelos.

The composition of the present invention should not be treated as an obvious one as
none of the citations are able to provide all the advantages of the present invention..
Objects of the Invention
The main object of the present invention is to provide a novel synergistic herbal
composition for the treatment of gastric ulcer.
Yet another object of the present invention is to provide a process for the preparation
of the composition.
Still another object of the present invention is to provide a method for the treatment of
gastric ulcer using the composition.
Summary of the Invention
The present invention provides a novel synergistic herbal composition for the
treatment of gastric ulcer. More particularly, th$ present invention relates to a novel
1
synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. Also, the present invention provides
a process for the preparation of the composition. The present invention further
provides a method for the treatment of gastric ulcer using said composition.
Detailed Description of the present Invention
In accordance with the first object of the present invention, there is provided a novel
synergistic herbal composition for the treatment of gastric ulcer, said composition
comprises an extract essentially obtained from one or more parts ofAegle marmelos and
Withania somnifra and optionally from one or more parts of Blechnum orintale, Vitis
vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper
longum and Azadirachta indica along with one or more pharmaceutically acceptable
additives/carriers.
More particularly, the present invention provides a novel synergistic herbal
composition for the treatment of gastric ulcer, said composition essentially comprises
4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from
Withania somnifra and optionally comprises 5-8 % by wt. of an extract from
Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an
extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum,
4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from
Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an
extract from Azadirachta indica along with one or more pharmaceutically acceptable
additives/carriers.
In an embodiment of the present invention, the extract is an aqueous extract.
In another embodiment of the present invention, the plant part of Aegle marmelos,
Withania somnifra and Blechnum orintale is root.
In still another embodiment of the present invention, the plant part of Vitis vinifera,
Feronia elephantum, Piper nigrum and Piper longum is fruit.
In yet another embodiment of the present invention, the plant part of Punica grantum is fruit
rind.
In one more embodiment of the present invention, the plant part of Ziniber officnale is
rhizome.
In one another embodiment of the present invention, the plant part of Azadirachta
indica is bark.
In accordance with the second object of the present invention, there is provided a
process for the preparation of the novel' synergistic herbal composition for the
treatment of gastric ulcer, said process comprising obtaining an extract essentially
from one or more parts of Aegle marmelos and Withania somnifra and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum and Azadirachta indica and mixing them with one or more pharmaceutically acceptable additives/carriers. In an embodiment of the present invention, said process extract is obtained by grinding 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica to a fine paste and mixing them with one or more pharmaceutically acceptable additives/carriers. In another embodiment of the present invention, the extract is an aqueous extract.
In still another embodiment of the present invention, the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
In yet another embodiment of the present invention, the plant part of Vitis vinifera,
Feronia elephantum, Piper nigrum and Piper longum is fruit.
In one more embodiment of the present invention, the plant part of Punica grantum is
fruit rind.
In one another embodiment of the present invention, the plant part of Ziniber officnale
is rhizome.
In an embodiment of the present invention, the plant part of Azadirachta indica is bark.
In accordance with the third object of the present invention, there is provided a method of treating gastric ulcer in a subject, said method comprises administering an effective amount of the synergistic herbal composition essentially comprises 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an
extract from Azadirachta indica along with one or more pharmaceutically acceptable
additives/carriers.
In an embodiment of the present invention, the subject is a mammal including human
being.
In another embodiment of the present invention, 50 to lOOmg of the composition is
administered per Kg of body weight to the subject.
In yet another embodiment of the present invention, the composition can be in the
form of tablets, capsules, syrup or by any other form known in the art.
In still another embodiment of the present invention, the composition is administered
orally, intra-muscularly, and by any other conventional methods.
In one more embodiment of the present invention, the composition may be used for
therapeutic as well as prophylactic treatment of gastric ulcer.
In one another embodiment of the present invention, the subject may be administered
a single bolus dose or a multiple dose.
Brief Description of the Tables
In the tables accompanying the specification,
Table 1 represents the effect of Omeprazole (a standard drug) and the new herbal
composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 2 compares the percentage protection of Omeprazole and the Herbal
composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 3 gives the effect of Omeprazole and the Herbal composition (HF) against
Aspirin induced ulcer model.
Table 4 gives the percentage protection of Omeprazole and the Herbal composition
(HF) against aspirin induced ulcer model.
Table 5 gives the effect of Omeprazole and the Herbal composition (HF) against
histamine induced duodenal ulcer in Guinea pig.
Table 6 gives the percentage protection of Omeprazole and the Herbal composition
(HF) against histamine induced duodenal ulcer in Guinea pigs.
Table 7 gives the effect of Omeprazole and the Herbal composition (HF) against
Ethanol Induced Ulcer Model.
Table 8 gives the percentage protection of Omeprazole and the Herbal composition
(HF) against Alcohol induced Ulcer Model.
Table 9 gives the effect of Omeprazole and the Herbal composition (HF) against
pyloric ligation induced Ulcer.
Table 10 gives the percentage protection of Omeprazole and the Herbal composition
(HF) against pyloric ligation induced Ulcer.
Table 11 gives the composition of the Herbal composition (HF) of the present
invention.
The present invention is further described with reference to the following experiments
which are given by way of illustration and therefore should not be construed to limit
the scope of the invention in any manner.
Experimental protocol: Invivo experiments:
The Applicants have carried out several experiments under different induced ulcer conditions and the effect of the herbal composition were studied and are tabulated herebelow. The effect of the herbal composition has been compared with respect to a known anti-ulcer drug "Omeprazole".
EXPERIMENT 1: EFFECT ON COLD RESTRAINT ULCERS (CRU) MODEL METHOD: Adult rats of either sex, weighing 150-175 grams are fasted for 24
hours in metallic cages with raised mesh bottoms to prevent coprophagia and were allowed free access to water. The test drugs were administered 45 minutes before immobilizing the animals. The rats were immobilized in the restraint cage and kept at 4°C in BOD incubator for 2 hours (According to the method of Senay and Levine 1967). The animals were sacrificed immediately after the restraint period. The abdomen was cut opened; stomach was taken out and incised along the greater curvature to observe the gastric lesions with the help of Magnascope (5X magnification)
The following arbitrary scoring system was used to grade the severity and intensity of the lesions:
1. Shedding of epithelium = 10
2. Petechial and frank hemorrhages = 20
3. One or two ulcers = 30
4. More than two ulcers = 40
5. Perforated ulcers = 50
The presence of any of these lesions was considered as a positive ulcerogenic response which has been shown as percentage uf rats showing gastric lesions. The
severity of ulcers is expressed in terms of ulcer index, which is the mean score of
gastric lesions of all the rats in a group. The term Ulcer Index is defined as:
Ulcer Index (U.I.) = Us + Up x 10'1
where Us = Mean severity of ulcer score and
Up = Percentage of animals with Ulcer incidences The percentage protection is calculated as follows: Percentage protection = (C-T/C) x 100. where C= Number of animals showing ulcer response in control group and
T= Number of animals showing ulcer response in test group.
The effect of the herbal composition of the present invention hereafter referred to as "HF" against Cold Restraint Ulcer Model (CRU) is given in Table 1. The effect of the standard drug "Omeprazole" is also given in Table 1 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against CRU model are tabulated in Table 2 given at the end of the description.
INFERENCE: The composition of the present invention is significantly effective in CRU model.
EXPERIMENT 2: EFFECT ON ASPIRIN INDUCED GASTRIC ULCER
MODEL
Method: Gastric ulceration was induced by aspirin according to the method of
Djahanguiri (1969). Aspirin (150 mg/Kg.) was administered per orally as a
suspension in gum-acacia and the animal was sacrificed 5 hr. after the aspirin
treatment and the ulcer index with protection index were calculated.
The effect of HF against aspirin induced gastric ulcer is given in Table 3. The effect of
the standard drug "Omeprazole" is also given in Table 3 given at the end of the
description.
Percentage protection of the herbal composition of the present invention (HF) and
Omeprazole against this model are tabulated in Table 4 given at the end of the
description.
INFERENCE: The herbal composition of the present invention is effective against
Aspirin induced gastric ulcer model.
EXPERIMENT 3: EFFECT ON HISTAMINE INDUCED ULCER MODEL
Method:
1. Animals were fasted for 24 hours with access to water.
2. The drug was given orally 1 hour prior to the histamine administration.
3. Histamine was administered in a dose of 0.25 mg/Kg, i.m. at 30 minutes
interval for 7 times and it induced 100 % duodenal ulceration in guinea pig
(According to the method of Watt and Eagleton 1964).
4. The animals were sacrificed after half an hour of last injection under ether
anesthesia.
5. The stomach along with duodenum were removed washed thoroughly and
examined for the lesions. Ulcer index and protection index were calculated.
The effect of HF against Histamine induced duodenal ulcer is given in Table 5. The effect of the standard drug "Omeprazole" is also given in Table 5 given at the end of
't ' • - •
the description.
Percentage protection of the herbal composition of the present invention (HF) and
Omeprazole against Histamine induced duodenal ulcer are tabulated in Table 6 given
at the end of the description.
INFERENCE: The Herbal composition of the present invention "HF" shows
significant anti ulcer effect against this model.
EXPERIMENT 4: EFFECT ON ALCOHOL INDUCED GASTRIC ULCERS IN
RATS
Method:
1. Adult rats of either sex were taken; weighing 150 - 175 grams were fasted for
24 hours with free access to water.
2. The test drugs were administered (p.o.) 45 minutes before alcohol
administration.
3. 1 ml of chilled absolute alcohol was administered (p.o.) to the rats (According
to the Wittetal).
4. Immediately after 1 hour, the animals were anesthetized, abdomen was cut
opened stomach was taken out and incised along the greater curvature to
observe the gastric lesions.
• The ulcers are examined under the 5X magnification with the help of magnascope.
• Absolute ethanol lesions appears as blackish lesions grouped in patches of
varying size, usually parallel to the major axis of the stomach.
5. The lengths of the lesions are measured and summated to give a total lesion score, then calculated and expressed in percentage.
The effect of HF against alcohol induced ulcer model is given in Table?. The effect of
the standard drug "Omeprazole" is also given in Table 7 given at the end of the
description.
Percentage protection of the herbal composition of the present invention (HF) and
Omeprazole against alcohol induced ulcer model are tabulated in Table 8 given at the
end of the description.
INFERENCE: The composition of the present invention does not show any
significant effect against alcohol induced gastric ulcer model.
EXPERIMENT 5: EFFECT ON PYLORIC LIGATION INDUCED ULCER
MODEL
Method:
1. Animals were fasted for 24 hours in the raised mesh bottom cages to prevent
coprophagia and were allowed free access to water.
2. The control group of rats was feed with the vehicle and the experimental
groups with their respective drugs 45 minutes prior to the ligation.
3. The animal was anesthetized, abdomen was cut opened under xiphoid process,
and the pyloric portion of the stomach was slightly lifted and ligated avoiding
any damage to the adjacent blood vessels (According to the method of Shay et
al. 1945).
4. The animals were stitched and kept for 4 hours with free access to water.
5. After 4 hours the animals were sacrificed under ether anesthesia and the
stomach was dissected out incised along the greater curvature.
6. The stomach was washed thoroughly and the ulcer index was scored as per in
other ulcer models.
The effect of HF against pyloric ligation induced ulcer is given in Table 9. The effect of the standard drug "Omeprazole" is also given in Table 9 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against pyloric ligation induced ulcer are tabulated in Table 10 given at
m
the end of the description.
INFERENCE: On comparison, Herbal composition shows high anti ulcer activity.
The anti ulcer activity of the herbal composition is higher than that of Omeprazole.
EXPERIMENT 6: HERBS AND PREPARATION OF THE COMPOSITION
Method:
For the purpose of conducting animal experiment all the herbs are washed dried and pulverized. All the herbs are taken in the proportion as shown in Table 11. To this water was added and boiled and concentrated to appropriate consistency. The components and their proportions of the standard "herbal composition " (HF) according to one embodiment of the present invention are listed in Tablell given at the end of the description. The parts of the herbs which can be used is also mentioned. The placebo preparation is designed to taste, smell and look like an Ayurvedic herbal formulation.
TABLE 1: Effect of New herbal composition (HF) against Cold Restraint Ulcer Model (CRU) with Omeprazole as a standard drug.

(Table Removed)
In the table, 10 = Shedding of epithelium; 20 = Petechial and frank hemorrhages; 30 = One or two ulcers; 40 = More than two ulcers; 50 = Perforated ulcers.
TABLE 2: Percentage protection of Herbal composition against Cold Restraint Ulcer Model (CRU) taking Omeprazole as a standard drug.
(Table Removed)
*The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 3: Effect of Herbal composition against Aspirin induced ulcer model with Omeprazole as a standard drug.
(Table Removed)
In the table, 10 = Shedding of epithelium; 20 = Petechial and frank hemorrhages; 30 - One or two ulcers; 40 = More than two ulcers; 50 = Perforated ulcers.
TABLE 4: Percentage protection of Herbal composition against aspirin induced ulcer model taking Omeprazole as a standard drug.
(Table Removed)
The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole. TABLE 5: Effect of Herbal composition against histamine induced duodenal ulcer in Guinea pig with Omeprazole as a standard drug.
(Table Removed)
TABLE 6: Percentage protection of Herbal composition against histamine induced duodenal ulcer in Guinea pig taking Omeprazole as a standard drug.
(Table Removed)

(Table Removed)
* The protection of omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of omeprazole. TABLE 9: Effect of Herbal composition against pyloric ligation induced Ulcer taking Omeprazole as a Standard drug
(Table Removed)
TABLE 10: Percentage protection of Herbal composition against pyloric ligation induced Ulcer Model taking Omeprazole as a standard drug.

(Table Removed)
* The protection of Omeprazole was taken as 100 % as it was the standard compound and the
percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 11: Composition of the Herbal composition (HF) of the present
invention.
(Table Removed)






We claim:
1. A synergistic herbal composition, wherein the said composition comprises:
[a] 4-10% by wt of an extract from Aegle marmelos;
[b] 4-11% by wt. of an extract from Withania somnifera; optionally along with
[c] 5-8% by wt. of an extract from Blechnum orientale;
[d] 5-11% by wt. of an extract from Vitis vinifera;
[e] 5-9% by wt. of an extract from Feronia elephantum;
[f] 8-11% by wt. of an extract from Punica granatum;
[g] 4-9% by wt. of an extract from Zingiber officinale;
[h] 2-11% by wt. of an extract from Piper nigrum;
[i] 8-12% by wt. of an extract from Piper longum, and [j] 2-11% by wt. of an extract from Azadirachta indica
along with one or more pharmaceutically acceptable additive(s) or carrier(s).
2. A composition as claimed in claim 1, wherein the extract is an aqueous extract.
3. A composition as claimed in claim 1, wherein the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is a root.
4. A composition as claimed in claim 1, wherein the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is a fruit.
5. A composition as claimed in claim 1, wherein the plant part of Punica grantum is a fruit rind.
6. A composition as claimed in claim 1, wherein the plant part of Ziniber officnale is a rhizome.

7. A composition as claimed in claim 1, wherein the plant part of Azadirachta indica is a bark.
8. A process for the preparation of a composition as claimed in claim 1, wherein the steps comprising mixing 4-10% by wt of an extract from Aegle marmelos; 4-11% by wt. of an extract from Withania somnifera; optionally along with 5-8% by wt. of an extract from Blechnum orientale; 5-11% by wt. of an extract from Vitis vinifera; 5-9% by wt. of an extract from Feronia elephantum; 8-11% by wt. of an extract from Punica granatum; 4-9% by wt. of an extract from Zingiber officinale; 2-11% by wt. of an extract from Piper nigrum; 8-12% by wt. of an extract from Piper longum, and 2-11% by wt. of an extract from Azadirachta indica with one or more pharmaceutically acceptable additive(s) or carrier(s).
9. A synergistic herbal composition for treating gastric ulcer and a process for the preparation thereof substantially as herein described with reference to the foregoing examples.



Documents:

2221-DELNP-2004-Abstract-(27-01-2009).pdf

2221-DELNP-2004-Abstract-(31-12-2008).pdf

2221-delnp-2004-abstract.pdf

2221-DELNP-2004-Claims-(27-01-2009).pdf

2221-DELNP-2004-Claims-(31-12-2008).pdf

2221-delnp-2004-claims.pdf

2221-DELNP-2004-Correspondence-Others-(31-12-2008).pdf

2221-delnp-2004-correspondence-others.pdf

2221-DELNP-2004-Description (Complete)-(27-01-2009).pdf

2221-DELNP-2004-Description (Complete)-(31-12-2008).pdf

2221-delnp-2004-description (complete).pdf

2221-DELNP-2004-Form-1-(27-01-2009).pdf

2221-DELNP-2004-Form-1-(31-12-2008).pdf

2221-delnp-2004-form-1.pdf

2221-delnp-2004-form-18.pdf

2221-DELNP-2004-Form-2-(27-01-2009).pdf

2221-DELNP-2004-Form-2-(31-12-2008).pdf

2221-delnp-2004-form-2.pdf

2221-DELNP-2004-Form-3-(31-12-2008).pdf

2221-delnp-2004-form-3.pdf

2221-DELNP-2004-Form-5-(31-12-2008).pdf

2221-delnp-2004-form-5.pdf

2221-DELNP-2004-Petition-137-(31-12-2008).pdf


Patent Number 232949
Indian Patent Application Number 2221/DELNP/2004
PG Journal Number 13/2009
Publication Date 27-Mar-2009
Grant Date 24-Mar-2009
Date of Filing 30-Jul-2004
Name of Patentee COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
Applicant Address RAFI MARG, NEW DELHI- 110 001, INDIA.
Inventors:
# Inventor's Name Inventor's Address
1 JANASWAMY MADHUSUDANA RAO INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY, HYDERABAD-500 007, INDIA.
2 UPPARAPALLI SAMPATH KUMAR INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY, HYDERABAD-500 007, INDIA.
3 BOGGAVARAPU SUBRAHMANYA SASTRY INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY, HYDERABAD-500 007, INDIA.
4 GAUTAM PALIT CENTRAL DRUG RESEARCH INSTITUTE, LUCKNOW-226 001, LUCKNOW.
5 JHILLU SINGH YADAV INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY, HYDERABAD-500 007, INDIA.
6 KONDAPURAM VIJAYA RAGHAVAN INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY, HYDERABAD-500 007, INDIA.
7 DEEPAK RAI CENTRAL DRUG RESEARCH INSTITUTE, LUCKNOW-226 001, LUCKNOW.
8 PANNIYAMPALLY MADHAVANKUTTY VARIER ARYA VAIDYA SALA, KOTTAKKAL-676503, INDIA
9 TRIKOVIL SANKARAN MURALEEDHARAN ARYA VAIDYA SALA, KOTTAKKAL-676503, INDIA
10 KOLLATH MURALEEDHARN ARYA VAIDYA SALA, KOTTAKKAL-676503, INDIA
PCT International Classification Number A61K 35/78
PCT International Application Number PCT/IB02/01122
PCT International Filing date 2002-03-25
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 NA